PR Newswire | 16 days 6 hours 51 minutes ago
DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.((R))
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc.( (R) )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan((R)) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan( )PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach((R)). DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our web site at www.dusapharma.com.
CONTACT: Chad Rubin, +1-646-378-2947, for DUSA Pharmaceuticals
Web site: http://www.dusapharma.com/
Articles appearing above are picked up from PR Newswire's feed. Stories from this feed are submitted by companies, edited and rereleased as a service of PR Newswire.
